Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Jan, 10.1038/s41388-022-02585-3, 2023)

被引：0
|
作者：
Bello Roufai, D.
Goncalves, A.
de la Motte Rouge, T.
Akla, S.
Blonz, C.
Grenier, J.
Gligorov, J.
Saghatchian, M.
Bailleux, C.
Simon, H.
Desmoulins, I.
Tharin, Z.
Renaud, E.
Bertho, M.
Benderra, M-a
Delaloge, S.
Robert, L.
Cottu, P.
Pierga, J. Y.
Loirat, D.
Bertucci, A.
Renouf, B.
Bidard, F. C.
Lerebours, F.
机构：
[1] Institut Curie,Department of Medical Oncology
[2] Institut Paoli Calmettes,Aix
[3] CRCM,Marseille Univ, CNRS, INSERM, Department of Medical Oncology
[4] Centre Eugène Marquis,Department of Medical Oncology
[5] Gustave Roussy,Department of Cancer Medicine
[6] Institut de Cancérologie de l’Ouest,Department of Medical Oncology
[7] Institut du Cancer d’Avignon,Department of Medical Oncology
[8] Hôpital Tenon,Department of Medical Oncology
[9] AP-HP,Breast Cancer Unit
[10] American Hospital of Paris,Department of Medical Oncology
[11] Centre Antoine Lacassagne,Department of Medical Oncology
[12] University Hospital of Brest,Department of Medical Oncology
[13] Centre Georges-François Leclerc,INSERM U938, Institut Universitaire de Cancérologie
[14] UVSQ,undefined
[15] Paris-Saclay University,undefined
[16] Paris Cité University,undefined
[17] AP-HP Sorbonne Université,undefined
来源：
ONCOGENE | 2023年 / 42卷 / 17期
关键词：
D O I：
10.1038/s41388-023-02615-8
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：1417 / 1417
页数：1
相关论文
共 50 条
  • [41] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
    Cardoso, F.
    Juric, D.
    Lerebours, F.
    Krop, I.
    Borrego, M. Ruiz
    Neven, P.
    Park, Y. H.
    Yardley, D.
    Jhaveri, K.
    Arce, C.
    Gu, E.
    Akdere, M.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S206 - S207
  • [42] Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
    Hoste, Griet
    Slembrouck, Laurence
    Jongen, Lynn
    Punie, Kevin
    Matton, Tom
    Vander Borght, Sara
    Vanden Bempt, Isabelle
    Menten, Johan
    Wildiers, Hans
    Floris, Giuseppe
    Arteaga, Carlos
    Neven, Patrick
    CLINICAL DRUG INVESTIGATION, 2018, 38 (11) : 1071 - 1075
  • [43] Palbociclib and endocrine therapy in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: The UK compassionate access program experience
    Battisti, N. M. L.
    Kingston, B.
    King, J.
    Denton, A.
    Waters, S.
    Sita-Lumsden, A.
    Rehman, F.
    Stavraka, C.
    Kristeleit, H.
    Sawyer, E.
    Houghton, D.
    Davidson, N.
    Howell, S.
    Choy, J.
    Harper, P.
    Roylance, R.
    Fharat, R.
    Mohammed, K.
    Ring, A.
    Johnston, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
    Griet Hoste
    Laurence Slembrouck
    Lynn Jongen
    Kevin Punie
    Tom Matton
    Sara Vander Borght
    Isabelle Vanden Bempt
    Johan Menten
    Hans Wildiers
    Giuseppe Floris
    Carlos Arteaga
    Patrick Neven
    Clinical Drug Investigation, 2018, 38 : 1071 - 1075
  • [45] Pik3ca mutations among hormone receptor positive and HER-2 negative advanced breast cancer patients in Finland
    Heinolainen, Krista
    Saarinen, Silva
    Ellonen, Antti
    Karlsson, Antti
    Utriainen, Meri
    Vertuani, Simona
    Holm, Barbro
    CANCER RESEARCH, 2021, 81 (04)
  • [46] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
    Rugo, Hope S.
    Borrego, Manuel Ruiz
    Chia, Stephen K. L.
    Juric, Dejan
    Turner, Nicholas C.
    Drullinsky, Pamela
    Lerebours, Florence
    Bianchi, Giulia Valeria
    Nienstedt, Carolyn C.
    Ridolfi, Antonia
    Thuerigen, Astrid
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer
    Seitz, K.
    Goossens, C.
    Huebner, H.
    Gass, P.
    Uhrig, S.
    Heindl, F.
    Emons, J.
    Ruebner, M.
    Anetsberger, D.
    Hartmann, A.
    Beckmann, M. W.
    Erber, R.
    Hack, C. C.
    Fasching, P. A.
    Haeberle, L.
    ESMO OPEN, 2024, 9 (11)
  • [48] Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B
    Juric, Dejan
    Turner, Nicholas
    Loi, Sherene
    Andre, Fabrice
    Chia, Stephen K.
    Jhaveri, Komal
    Neven, Patrick
    Dent, Rebecca
    Ciruelos, Eva
    Joshi, Mukta
    Roux, Estelle
    Patino, Heather
    Akdere, Murat
    Rugo, Hope
    CANCER RESEARCH, 2023, 83 (05)
  • [49] Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) plus fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
    Andre, F.
    Rugo, H. S.
    Juric, D.
    Rubovsky, G.
    Yamashita, T.
    Stemmer, S. M.
    Lu, Y- S.
    Miller, M. K.
    Lorenzo, I.
    Hu, H.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S498 - S499
  • [50] PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories
    Pepe, Francesco
    Venetis, Konstantinos
    Cursano, Giulia
    Frascarelli, Chiara
    Pisapia, Pasquale
    Vacirca, Davide
    Scimone, Claudia
    Rappa, Alessandra
    Russo, Gianluca
    Mane, Eltjona
    Pagni, Fabio
    Castellano, Isabella
    Troncone, Giancarlo
    Angelis, Carmine De
    Curigliano, Giuseppe
    Guerini-Rocco, Elena
    Malapelle, Umberto
    Fusco, Nicola
    PHARMACOGENOMICS, 2024, 25 (03) : 161 - 169
12345